Hepatitis E

Lore & Background

The hepatitis E virus was discovered in 1983 by researchers investigating an outbreak of unexplained hepatitis among Soviet soldiers in Afghanistan. Russian virologist Mikhail S. Balayan identified the virus after ingesting fecal samples of nine soldiers mixed with kefir. The earliest well-documented epidemic occurred in 1955 in New Delhi, affecting tens of thousands of people, with HEV later identified retrospectively from stored samples.

Hepatitis E has an average incubation period of 40 days, ranging from 2 to 8 weeks. Most infections are asymptomatic, but symptomatic cases may include jaundice, fatigue, and nausea. The virus is primarily transmitted via the fecal-oral route through contaminated water or food. Genotypes 1 and 2 are restricted to humans and often cause large outbreaks in developing countries, while genotypes 3 and 4 are zoonotic, infecting humans, pigs, and other animals.

In pregnant women, especially in the third trimester, hepatitis E can be severe, with death rates around 20% due to fulminant liver failure. Organ transplant recipients on immunosuppressive medications may develop chronic hepatitis E, diagnosed after 3 months of continuous viremia. The virus can also cause neurological complications, acute pancreatitis, and other organ problems.

Reader's Guide

Hepatitis E represents a significant global health burden, with an estimated 19 million infections in 2017. The disease is most common in men aged 15 to 35 years. Genotypes 1 and 2 cause large waterborne outbreaks in regions with poor sanitation, particularly in Asia and Africa, while genotypes 3 and 4 cause sporadic zoonotic cases in industrialized countries. The discovery of the virus in 1983 by Mikhail Balayan, through a self-experiment, marked a pivotal moment in virology. A preventive vaccine (HEV 239) is approved for use in China, but no global vaccine program exists. The disease's severity in pregnancy remains poorly understood, with hormonal changes and viral replication in the placenta suspected. Chronic infection in immunosuppressed individuals, such as organ transplant recipients, can lead to cirrhosis. The virus's ability to infect animals, particularly pigs, underscores its zoonotic potential and the need for food safety measures, such as cooking meat to 70°C for 20 minutes. Hepatitis E continues to be a focus of research due to its varied clinical presentations and global distribution.

Did You Know?

• The hepatitis E virus was discovered in 1983 after Russian virologist Mikhail S. Balayan ingested fecal samples of nine soldiers mixed with kefir.
• The earliest well-documented epidemic of hepatitis E occurred in 1955 in New Delhi, affecting tens of thousands of people.
• In pregnant women, especially in the third trimester, hepatitis E can cause fulminant liver failure with death rates around 20%.
• A preventive vaccine (HEV 239) is approved for use in China.

Classification Among the Five Hepatotropic Viruses

Hepatitis E occupies a distinct position within the family of liver-infecting agents. It is one of five hepatotropic viruses—alongside hepatitis A, B, C, and D—that account for the most common causes of viral hepatitis worldwide. A critical point is that these five viruses are unrelated to one another; they do not share a common lineage, yet each independently targets the liver and produces inflammation. This distinction matters because it means the immune response to one does not confer protection against another. Beyond these five primary culprits, a broader range of viruses—including cytomegalovirus, Epstein–Barr virus, yellow fever, and even herpes simplex virus—have been documented as capable of triggering liver inflammation, though they are not classified as the principal hepatotropic agents. Understanding where hepatitis E sits within this taxonomy helps clinicians and public-health officials recognize that hepatitis is not a single disease but a syndrome with multiple, biologically distinct viral origins requiring different diagnostic and management approaches.

Transmission Pathway and Self-Limited Clinical Course

The route by which hepatitis E reaches a human host distinguishes it from the blood-borne hepatitis viruses. Like hepatitis A, it is transmitted through contaminated food or water, placing it in the food-and-water transmission category rather than the parenteral one. This pathway carries a significant clinical implication: viruses spread this way are predominantly self-limited. In practical terms, a person infected with hepatitis E typically experiences an acute episode of illness that resolves on its own, without progressing to the chronic, long-lasting liver damage characteristic of hepatitis B or C. The blood-borne counterparts, by contrast, can establish persistent infection, advance through long periods of asymptomatic damage, and ultimately culminate in decompensated hepatic disease or hepatocellular carcinoma. Because hepatitis E follows this self-limited trajectory, the clinical course is fundamentally different from that of the chronic forms. There is no ongoing viral replication driving progressive fibrosis in the typical presentation, and the disease does not carry the same long-term risk of cirrhosis or liver cancer that defines the natural history of hepatitis B and C. This distinction shapes how public-health systems prioritize surveillance and intervention for each type.

Prevention Landscape and the Vaccination Gap

Among the five major hepatotropic viruses, the prevention landscape is uneven. Hepatitis A and hepatitis B both have available vaccines that can prevent infection, and effective treatments for hepatitis C exist, though they are described as costly. Hepatitis E, however, does not appear in the available information as having a dedicated vaccine or a specific antiviral treatment regimen mentioned. This gap is notable because the virus's primary route of entry—contaminated food and water—means that prevention depends heavily on the quality of water supply and food safety infrastructure rather than on individual immunization. In regions where these systems are underdeveloped, the risk of outbreak remains elevated. The self-limited nature of the illness does reduce the urgency for long-term medical intervention compared with chronic hepatitis, yet the acute phase still demands medical attention and supportive management. The contrast between the well-established vaccine programs for A and B and the absence of a comparable tool for E highlights an area where public-health investment and research could yield significant benefits, particularly in communities most vulnerable to waterborne transmission.

Global Mortality Context and Regional Disparities

Hepatitis E exists within a broader global burden of viral hepatitis that claims a staggering number of lives each year. In 2013, approximately 1.5 million people worldwide died as a result of viral hepatitis, with the majority of those deaths attributed to hepatitis B and C rather than to the water-borne types. This mortality pattern reflects the chronic, progressive nature of blood-borne hepatitis, which can silently damage the liver over decades before manifesting as cirrhosis or hepatocellular carcinoma. East Asia, and Mongolia in particular, was identified as the region most heavily affected by the overall burden. While hepatitis E's self-limited course means it is less likely to be a direct driver of this long-term mortality, it still contributes to the acute illness burden in communities with limited healthcare access. The fact that the five hepatotropic viruses are biologically unrelated means that the epidemiological, clinical, and public-health strategies for each must be tailored individually. A comprehensive understanding of viral hepatitis therefore requires tracking each virus's distinct transmission ecology, natural history, and regional prevalence rather than treating hepatitis as a monolithic condition.

Gallery